Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO Steven HutchensYefim ManevichDanyelle M. Townsend PRECLINICAL STUDIES 16 March 2010 Pages: 719 - 729
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity Jérôme DevyFarid OuchaniEmmanuelle Charpentier PRECLINICAL STUDIES 28 March 2010 Pages: 730 - 741
In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes Georgi MomekovMargarita KaraivanovaPanayot R. Bontchev PRECLINICAL STUDIES 13 March 2010 Pages: 742 - 751
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells Norma O’DonovanAnnette T. ByrneJohn Crown PRECLINICAL STUDIES 16 March 2010 Pages: 752 - 759
An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities Julio BenitesJaime A. ValderramaPedro Buc Calderon Preclinical Studies 17 March 2010 Pages: 760 - 767
Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice Roos L. OostendorpT. BuckleO. van Tellingen PRECLINICAL STUDIES Open access 13 April 2010 Pages: 768 - 776
A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis Esther A. GuzmánJacob D. JohnsonAmy E. Wright PRECLINICAL STUDIES 30 March 2010 Pages: 777 - 785
5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis Danqing XuJi CaoBo Yang PRECLINICAL STUDIES 30 March 2010 Pages: 786 - 799
D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα Min GuiDa-Kuo ShiJian Ding PRECLINICAL STUDIES 25 March 2010 Pages: 800 - 810
The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity Pere TubertMontserrat RodríguezMaria Vilanova PRECLINICAL STUDIES 30 March 2010 Pages: 811 - 817
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor Alfonso Quintás-CardamaTaghi ManshouriSrdan Verstovsek PRECLINICAL STUDIES 07 April 2010 Pages: 818 - 826
Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line Yukako FukushiMasaharu HazawaIkuo Kashiwakura PRECLINICAL STUDIES 27 April 2010 Pages: 827 - 832
Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain Meaghan MacPheeZakaria RachidBertrand J. Jean-Claude PRECLINICAL STUDIES 29 April 2010 Pages: 833 - 845
MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis Piotr JasinskiPawel ZwolakArkadiusz Z. Dudek PRECLINICAL STUDIES 16 April 2010 Pages: 846 - 852
NSC126188, a piperazine alkyl derivative, induces apoptosis via upregulation of RhoB in HeLa cells Bo-Kyung KimDong-Myung KimMisun Won PRECLINICAL STUDIES 30 April 2010 Pages: 853 - 860
A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice Jin-Bin JiaWen-Quan WangZhao-You Tang PRECLINICAL STUDIES 23 April 2010 Pages: 861 - 872
Intercalative pyrimido[4′,5′:4,5]thieno(2,3-b)quinolines induce apoptosis in leukemic cells: a comparative study of methoxy and morpholino substitution M. S. ShahabuddinMridula NambiarSathees C. Raghavan PRECLINICAL STUDIES 28 April 2010 Pages: 873 - 882
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity In Hae ParkJin Young KimJi-Youn Han PRECLINICAL STUDIES 14 May 2010 Pages: 883 - 890
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study Raphaël BeckRozangela Curi PedrosaJulien Verrax PRECLINICAL STUDIES 08 May 2010 Pages: 891 - 900
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs Pamela W. LucasJoanna M. SchmitTimothy M. Fan PRECLINICAL STUDIES 25 May 2010 Pages: 901 - 911
Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration Amel DudakovicHuaxiang TongRaymond J. Hohl PRECLINICAL STUDIES 18 May 2010 Pages: 912 - 920
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor Makiko KobayashiIkuko Takahashi-SuzukiHiroshi Hirai PRECLINICAL STUDIES 04 June 2010 Pages: 921 - 931
Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands Beatriz GallegoMilena R. KaluđerovićSantiago Gómez-Ruiz PRECLINICAL STUDIES 15 May 2010 Pages: 932 - 944
Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin Ki-Eun HwangKyoung-Suk NaHak-Ryul Kim PRECLINICAL STUDIES 13 May 2010 Pages: 945 - 952
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib Neeltje SteeghsRon H. J. MathijssenHenk-Jan Guchelaar PHASE I STUDIES Open access 25 February 2010 Pages: 953 - 962
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer Donald A. RichardsDavid LoeschDatchen F. Tai PHASE I STUDIES 30 March 2010 Pages: 963 - 970
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies Peter S. GalatinRanjana H. AdvaniBranimir I. Sikic PHASE I STUDIES 28 March 2010 Pages: 971 - 977
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors Hanna K. SanoffJanine M. DaviesE. Claire Dees PHASE I STUDIES 13 April 2010 Pages: 978 - 983
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies Elena SotoRon J. KeizerMats O. Karlsson PHASE I STUDIES Open access 07 May 2010 Pages: 984 - 995
A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies Benoit YouAnthony BradeEric X. Chen PHASE I STUDIES 08 May 2010 Pages: 996 - 1003
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors Mark Andrew DicksonDana E. RathkopfGary K. Schwartz PHASE I STUDIES 12 May 2010 Pages: 1004 - 1012
A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials Som D. MukherjeeMegan E. CoombesAndrew Arnold PHASE I STUDIES 29 May 2010 Pages: 1013 - 1020
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens Jaafar BennounaIstvan LangJean-Yves Douillard PHASE II STUDIES 02 February 2010 Pages: 1021 - 1028
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction Juan W. ValleAnne ArmstrongMalcolm Ranson PHASE II STUDIES 24 February 2010 Pages: 1029 - 1037
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143) José María ViéitezManuel ValladaresAngel Jiménez Lacave PHASE II STUDIES 06 March 2010 Pages: 1038 - 1044
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium Srikala S. SridharEric WinquistMalcolm J. Moore PHASE II STUDIES 27 February 2010 Pages: 1045 - 1049
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer Sung Yong OhYoung-Tae JuJung Hun Kang PHASE II STUDIES 19 March 2010 Pages: 1050 - 1056
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer Colin D. WeekesSujatha NallapareddyWells A. Messersmith PHASE II STUDIES 23 March 2010 Pages: 1057 - 1065
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness Sung Yong OhChi Young JeongJung Hun Kang Phase II Studies 01 April 2010 Pages: 1066 - 1072
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer Sang Joon ShinJae Heon JeongJoong Bae Ahn PHASE II STUDIES 21 March 2010 Pages: 1073 - 1080
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer Achillia LakkaIlias MylonisAndreas Tsakalof SHORT REPORT 01 May 2010 Pages: 1081 - 1089
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib Romain CoriatStanislas RopertFrançois Goldwasser SHORT REPORT 05 June 2010 Pages: 1090 - 1093
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model Stefan FaderlCarlos Bueso-RamosZeev Estrov SHORT REPORT 03 June 2010 Pages: 1094 - 1097
Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan Moon Jin KimGyeong-Won LeeCheolwon Suh SHORT REPORT 21 May 2010 Pages: 1098 - 1101
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide Catherine J. DrummondGraeme J. FinlayBruce C. Baguley SHORT REPORT 22 June 2010 Pages: 1102 - 1110
Ultraviolet recall dermatitis reaction with sorafenib Nicolas MagnéCyrus ChargariJean-Philippe Spano SHORT REPORT 22 June 2010 Pages: 1111 - 1113
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) Yevgeniy BalagulaKatherine Barth HustonPatricia L. Myskowski REVIEW 27 October 2010 Pages: 1114 - 1121
Erratum to: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs Joseph A. BauerGerald FryePeter Brofman Erratum 03 May 2011 Pages: 1122 - 1122